Published in J Clin Densitom on February 16, 2007
Appropriate osteoporosis treatment by family physicians in response to FRAX vs CAROC reporting: results from a randomized controlled trial. J Clin Densitom (2013) 2.05
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12
Comparison between various fracture risk assessment tools. Osteoporos Int (2014) 1.00
Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord (2011) 0.98
The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromsø, Norway. Eur J Epidemiol (2009) 0.95
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93
A clinical decision rule to enhance targeted bone mineral density testing in healthy mid-life women. Osteoporos Int (2011) 0.91
Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program. Osteoporos Int (2013) 0.88
Validation of a case definition for osteoporosis disease surveillance. Osteoporos Int (2010) 0.88
Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol (2009) 0.87
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int (2009) 0.86
Development of a prototype clinical decision support tool for osteoporosis disease management: a qualitative study of focus groups. BMC Med Inform Decis Mak (2010) 0.86
How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine (2013) 0.83
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int (2009) 0.79
NICE continues to muddy the waters of osteoporosis. Osteoporos Int (2008) 0.78
Determining whether women with osteopenic bone mineral density have low, moderate, or high clinical fracture risk. Menopause (2010) 0.77
Combined vertebral fracture assessment and bone mineral density measurement: a patient-friendly new tool with an important impact on the Canadian Risk Fracture Classification. Can Assoc Radiol J (2010) 0.77
PUFAs, Bone Mineral Density, and Fragility Fracture: Findings from Human Studies. Adv Nutr (2016) 0.76
Our approach to osteoporosis screening and treatment needs to change. CMAJ (2008) 0.75
Estimating the long-term functional burden of osteoporosis-related fractures. Osteoporos Int (2017) 0.75
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab (2005) 5.64
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet (2002) 3.00
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54
Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res (2015) 2.52
Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom (2005) 2.44
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res (2011) 2.24
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol (2008) 2.19
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol (2008) 2.04
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. Diabetes Care (2002) 1.88
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res (2012) 1.82
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr (2005) 1.80
Report of a summit on molecular imaging. Radiology (2005) 1.79
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am (2006) 1.72
Effect of a low glycaemic index diet on blood glucose in women with gestational hyperglycaemia. Diabetes Res Clin Pract (2010) 1.71
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int (2012) 1.64
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology (2009) 1.59
Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med (2016) 1.56
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture. J Bone Miner Res (2009) 1.54
A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract (2011) 1.50
The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism (2003) 1.49
Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol (2003) 1.48
Therapy insight: Osteoporosis in inflammatory bowel disease--advances and retreats. Nat Clin Pract Gastroenterol Hepatol (2005) 1.48
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord (2002) 1.47
Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. Int J Cardiovasc Imaging (2007) 1.46
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause (2015) 1.45
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ (2010) 1.45
The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol (2013) 1.44
Osteonecrosis of the jaw and bisphosphonates. BMJ (2010) 1.41
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol (2013) 1.40
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J (2007) 1.32
Management of osteoporosis in men: an update and case example. CMAJ (2007) 1.29